Terms: = Pancreatic cancer AND NT5C2, ENSG00000076685, 22978, P49902, PNT5, NT5B, GMP, cN-II AND Prognosis
5 results:
1. Prognostic Effect of Preoperative Inflammatory Markers on Morbidity and Overall Survival in pancreatic Adenocarsinoma.
Çaparlar MA; Durhan A; Süleymanov M; Binarbaşı C; Koşmaz K
Niger J Clin Pract; 2023 Dec; 26(12):1902-1909. PubMed ID: 38158359
[TBL] [Abstract] [Full Text] [Related]
2. High-Load Gemcitabine Inorganic-Organic Hybrid Nanoparticles as an Image-Guided Tumor-Selective Drug-Delivery System to Treat pancreatic cancer.
Ischyropoulou M; Sabljo K; Schneider L; Niemeyer CM; Napp J; Feldmann C; Alves F
Adv Mater; 2023 Nov; 35(46):e2305151. PubMed ID: 37587542
[TBL] [Abstract] [Full Text] [Related]
3. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
[TBL] [Abstract] [Full Text] [Related]
4. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer.
Kabashima A; Matsuo Y; Ito S; Akiyama Y; Ishii T; Shimada S; Masamune A; Tanabe M; Tanaka S
Sci Rep; 2022 Jun; 12(1):10466. PubMed ID: 35773436
[TBL] [Abstract] [Full Text] [Related]
5. Blocking CD47 promotes antitumour immunity through CD103
Wang S; Wu Q; Chen T; Su R; Pan C; Qian J; Huang H; Yin S; Xie H; Zhou L; Zheng S
J Hepatol; 2022 Aug; 77(2):467-478. PubMed ID: 35367532
[TBL] [Abstract] [Full Text] [Related]
